U.S. Markets closed
  • S&P Futures

    3,647.00
    +14.25 (+0.39%)
     
  • Dow Futures

    30,106.00
    +108.00 (+0.36%)
     
  • Nasdaq Futures

    12,153.00
    +77.00 (+0.64%)
     
  • Russell 2000 Futures

    1,857.30
    +5.80 (+0.31%)
     
  • Crude Oil

    45.37
    +0.46 (+1.02%)
     
  • Gold

    1,806.30
    +1.70 (+0.09%)
     
  • Silver

    23.33
    +0.03 (+0.15%)
     
  • EUR/USD

    1.1909
    +0.0013 (+0.1072%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3362
    +0.0004 (+0.0267%)
     
  • USD/JPY

    104.5280
    +0.0480 (+0.0459%)
     
  • BTC-USD

    18,926.99
    -141.50 (-0.74%)
     
  • CMC Crypto 200

    375.51
    +5.76 (+1.56%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,581.98
    +416.39 (+1.59%)
     

Avenue Therapeutics Trades Higher After Phase 3 Success

Tanzeel Akhtar

Avenue Therapeutics (NASDAQ: ATXI)'s second Phase 3 trial of IV tramadol for the treatment of postoperative pain following abdominoplasty is a success.

The announcement said the trial met all of its key secondary endpoints. The study also includes a standard-of-care IV opioid as an active comparator: IV morphine 4 mg. In this study, IV tramadol also demonstrated similar efficacy and safety to that of IV morphine.

“The strong safety and efficacy results from this second Phase 3 trial are consistent with those from the first Phase 3 trial in bunionectomy surgery and demonstrated the utility of IV tramadol in post-surgical pain management regardless of the surgery type,” said CEO Lucy Lu in a press release. “This study is a significant milestone for Avenue because it brings us one step closer to submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), currently planned for year-end 2019."

Avenue Therapeutics is trading up 10.3 percent at $5.74 per share Monday afternoon. The stock soared as high as 30 percent earlier in the day.

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.